Cancer vaccine trial disappointment for Immune Design

15 October 2018
2019_biotech_test_vial_discovery_big

Shares in West Coast, USA-based oncology specialist Immune Design (Nasdaq: IMDZ) have fallen more than a third since it announced an unfavorable early analysis of a Phase II trial of its cancer vaccine candidate CMB305.

The firm announced it would stop the trial into CMB305, which was testing the candidate in combination with Roche’s (ROG: SIX) Tecentriq (atezolizumab), in relapsed synovial sarcoma patients.

Data from the SYNOVATE trial showed the therapy was not likely to show a survival benefit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology